The PEAK data and Priority Review are strong catalysts; the stock may re-rate upward as the market prices in a high-probability approval and commercial launch in 2H 2026. Traders should watch for the PDUFA date (Nov 30, 2026) and any updates on the first-line exon 9 cohort. Given the historical underperformance of prior bullish calls on COGT (avg T+20 alpha -9.5%), consider taking profits on strength and monitoring for potential sell-the-news after the ASCO presentation.
Price Chart
Executive Summary
Cogent Biosciences reported highly positive Phase 3 PEAK trial results for bezuclastinib in combination with sunitinib in second-line GIST, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (median PFS 16.5 months vs 9.2 months, HR=0.50, p<0.0001) and objective response rate (46% vs 26%) compared to sunitinib alone. The FDA has granted Priority Review for the NDA with a PDUFA date of November 30, 2026, and the company plans to launch later this year. This is a transformative event for the company, as bezuclastinib is its lead asset and the data position it as a potential new standard of care in a large market.
Key Facts
- Bezuclastinib combination reduced risk of disease progression or death by 50% vs sunitinib alone (HR=0.50, 95% CI: 0.39-0.65, p<0.0001)
- Median PFS: 16.5 months for combination vs 9.2 months for sunitinib monotherapy
- Objective response rate: 46% for combination vs 26% for sunitinib
- FDA granted Priority Review for NDA; PDUFA date November 30, 2026
- Mean duration of treatment on combination arm estimated at 21.4 months
- PFS2 (time to progression on next therapy or death) median not reached vs 21 months (HR=0.57)
- Safety profile generally consistent with sunitinib alone; no unique combination risks observed
- Initiated new clinical trial of bezuclastinib combination in first-line GIST patients with KIT exon 9 mutations
Financial Impact
Transformative for a $6.0B market cap company with a single lead asset; potential peak sales in GIST could exceed $1B annually given standard-of-care positioning in second-line and expansion into first-line
Risk Factors
- PDUFA delay or complete response letter (CRL) from FDA, especially on CMC or safety grounds
- Competition from other KIT inhibitors (e.g., ripretinib, avapritinib) in GIST
- Commercial execution risk for a first launch by a small biotech
- Potential transient ALT/AST elevations requiring monitoring and dose management
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303872 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.07 (−25.20%) |
Aug 10, 2026 7w ago | Press Release | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.07 (−25.20%) |
Aug 9, 2026 7w ago | Institutional Cluster | $41.53 $35.28 | ▼ −15.05% | ▼ −14.13% | $31.07 (−25.20%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.07 (−6.15%) |
Jun 12, 2026 16w ago | Press Release | $33.10 $38.87 | ▲ +17.43% | ▲ +15.65% | $31.07 (−6.15%) |
May 30, 2026 17w ago | Press Release | $34.81 $38.70 | ▲ +11.18% | ▲ +12.47% | $31.07 (−10.76%) |
May 28, 2026 18w ago | Press Release | $35.38 $38.10 | ▲ +7.69% | ▲ +10.83% | $31.07 (−12.20%) |
May 5, 2026 21w ago | 8-K | $36.98 $32.76 | ▼ −11.41% | ▼ −16.37% | $31.07 (−16.00%) |
Apr 17, 2026 24w ago | Press Release | $37.25 $34.19 | ▼ −8.21% | ▼ −13.59% | $31.07 (−16.60%) |
Apr 1, 2026 26w ago | Press Release | $35.24 $35.87 | ▲ +1.79% | ▼ −7.93% | $31.07 (−11.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access